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Correction to: Scientific Reports https://doi.org/10.1038/s41598-017-17119-1, published online 04 December 
2017
This Article contains errors.
In Figure 5A, the actin loading control western blot is missing a lane. The correct Figure 5 appears below as 
Figure 1.
In addition, in the Results section under the sub-heading ‘Platinum and PARP inhibitor sensitivity’,
“There was no overall difference between the sensitivity of Trp53−/−−/−;Brca1−/− and Trp53−/−;Brca2−/− cells.”
should read:
“There was no overall difference between the sensitivity of Trp53−/−;Brca1−/− and Trp53−/−;Brca2−/− cells.”
Finally, in the Discussion section,
“Using one of our previous Trp53−/− clones, we have generated further double mutants, with deletions in Brca1, 
Pten and Nf1 in addition to loss Trp53, as well as triple mutants lacking Trp53, Brca2 and Pten.”
should read:
“Using one of our previous Trp53−/− clones, we have generated further double mutants, with deletions in Brca1, 
Pten and Nf1 in addition to loss of Trp53, as well as triple mutants lacking Trp53, Brca2 and Pten.”
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Figure 1. Generation and evaluation of Dicer−/−; Pten−/−; Trp53−/− TKO cells. (A) OvidT 497 Dicer−/−; 
Pten−/− (DKO) cells were transfected with PX459 encoding Trp53 gRNA. Clone 4 contained no Trp53 mutation; 
clone 13 (TKO) contained bi-allelic Trp53 exon 5 mutations. Expression of PTEN and p53 was assessed 
by immunoblot (left). F3 = ID8 Trp53−/−. Sensitivity to Nutlin-3 was assessed by MTT assay (right). (B) 
Homologous recombination was assessed in DKO 4 and TKO 13 cells as previously. (C) Sensitivity of DKO 4 
and TKO 13 cells to cisplatin. Each dot represents one triplicate experiment. Bars represent median. *p < 0.01. 
(D) Cells (5 × 106) were injected intraperitoneally into female C57Bl/6 mice in groups of six. Mice were killed 
when they reached humane endpoints. Excised tumours were fixed in formalin and stained for WT1 and PAX8. 
Each TKO 13 section comes from a separate mouse. Positive controls (+ve) are ID8 tumour (WT1) and normal 
mouse fallopian tube (PAX8), both from14. Bars represent 50 μm.
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Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
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